NEO100
-
NeOnc’s Patent Portfolio: Beyond a Single Drug for NTHI
NeOnc Technologies’ NEO100 shows promising Phase 2a results for recurrent high-grade glioma, with a 48.9% six-month PFS. This highlights their proprietary intranasal nose-to-brain delivery platform, supported by extensive patents. The platform’s potential extends beyond oncology, with preclinical data suggesting enhanced co-delivery of other drugs. NeOnc is pursuing FDA alignment for a registrational path.
